NDASUBCUTANEOUSSOLUTION
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
6/8 — Strong
RASUVO (methotrexate) by Medexus Pharmaceuticals is reductase. Approved for rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RASUVO (methotrexate) is a subcutaneous solution approved in 2014 for breast cancer, rheumatoid arthritis, and psoriasis. It works by inhibiting dihydrofolate reductase, which blocks the conversion of dihydrofolates to tetrahydrofolates needed for DNA synthesis and cellular replication. This mechanism makes it particularly effective against rapidly proliferating cells including malignant cells and immune-activated tissues. RASUVO represents a convenient subcutaneous formulation of a classic small-molecule antimetabolite with decades of clinical experience.
$0.0BPart D
3.1 years to LOEMechanism of Action
reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively…
Indications (3)
Worked on RASUVO at Medexus Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.